| Autor: |
Cvitanović-Šojat, Ljerka, Mučić-Pucić, Branka, Sabol, Z, Šepić Grahovac, Dubravka, Hajnzić, Tomislav-Franjo, Sojat, T. |
| Přispěvatelé: |
Avanzini, Giuliano |
| Jazyk: |
angličtina |
| Rok vydání: |
2003 |
| Předmět: |
|
| Popis: |
The purpose of the study was to analyse and summarise the efficacy and safety of topiramate (TPM), introduced as add-on AED and switched to monotherapy or introduced as first-line AED. We reviewed the case records of 80 children treated with TPM between years 1998 and 2002 (in-clinic and out-clinic). The follow-up lasted 6 months to 4 years. The age range was from 1 to 21 years ; there were 40% girls and 60% boys. In 75 patients mean age of onset of seizures was 2.93 years, mean duration of epilepsy was 9.41 years. In 5 children epilepsy was recently diagnosed. In 64.4% epilepsy was complex partial, in 6.6% generalized, in 4.4% myoclonic, 15.5% had Lennox-Gastaut syndrome and 8% multiple seizures. Epilepsy was symptomatic in 49% and idiopathic/cryptogenic in 51%. Clinical characteristics of the patients and the outcome of the treatment were recorded. 75 children had first failed trials on conventional AEDs. TPM was administrated as add-on and titrated to target dose of 6-9mg/kg. 33.3% of patients became seizure-free. They were ten switched to TPM monotherapy and remained seizure-free. For five children TPM has been used as first line AED. Four become and remained seizure-free. The body with Lennox-Gastaut syndrome had seizure reduction of 50% in monotherapy the daily dose of TPM was 100-200mg. During TPM monotherapy no side effect were observed. Data analysis showed maintained efficacy and no side effects with low-dose TPM monotherapy in different types of epilepsy in children. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
